Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences

January 18, 2024

Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.

Buyers
Kindeva Drug Delivery, Altaris, LLC
Targets
Summit Biosciences, Inc.
Sellers
Founding family shareholders
Platforms
Kindeva Drug Delivery
Industry
Medical Devices
Location
Kentucky, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.